Who
Bethany Sensenig
Director
Company insider
Files Form 4 as: Director, KalVista Pharmaceuticals; Director, Alpha Cognition; Director, Supernus Pharmaceuticals; Chief Financial Officer, 9 Meters Biopharma.
In numbers
- Trades disclosed
- 30
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $694K
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 18 Jan 2022
- Last trade
- 11 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 11 Jun 2026filed 11 Jun 2026 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —45,000 | filing |
| 16 Apr 2026filed 17 Apr 2026 | ACOG Alpha CognitionBiotechnology | SEC FORM 4 Code A | —5,489 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | ACOG Alpha Cognitionoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,991 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | ACOG Alpha Cognitionoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,991 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | ACOG Alpha CognitionBiotechnology | SEC FORM 4 Code A | —5,489 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —4,475 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $61K1,217 at $50.31 | filing |
| 19 Feb 2026filed 23 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $167K3,258 at $51.27 | filing |
| 19 Feb 2026filed 23 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,475 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,475 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —4,475 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $61K1,217 at $50.31 | filing |
| 19 Feb 2026filed 23 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $167K3,258 at $51.27 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,989 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,977 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,989 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,977 at $0.00 | filing |
| 1 Oct 2025filed 2 Oct 2025 | KalVista Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 14 Aug 2025filed 18 Aug 2025 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $227K5,369 at $42.25 | filing |
News
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026SUPN · manilatimes.net · 19 Oct 2026Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveySUPN · tickerreport.com · 11 Oct 2026Shineco (NASDAQ:SISI) vs. Supernus Pharmaceuticals (NASDAQ:SUPN) Financial AnalysisSUPN · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Bethany Sensenig; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.